Related Experiment Video

Updated: Aug 16, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Characterization of monoclonal antibodies directed against trail or trail receptors

Claudine Vermot-Desroches1, Elise Sergent, Brigitte Bonnin

  • 1Diaclone Research, 1, Bd Fleming, 25020 Besançon Cedex, France.

Cellular Immunology
|September 15, 2005
PubMed

Insights

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers cancer cell death. Researchers evaluated monoclonal antibodies for TRAIL and its receptors, finding some could control TRAIL-induced apoptosis.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Biology

Background:

  • Tumor necrosis factor receptor superfamily members mediate programmed cell death signals, known as "death receptors."
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in tumor cells, sparing normal cells.
  • Five TRAIL receptors exist: TRAIL R1 (DR4), TRAIL R2 (DR5), TRAIL R3 (DcR1), TRAIL R4 (DcR2), and osteoprotegerin.

Purpose of the Study:

  • To determine the specificity of 10 monoclonal antibodies (mAbs) against TRAIL and its receptors.
  • To investigate the expression of TRAIL and its receptors using these mAbs.
  • To assess the ability of these mAbs to modulate TRAIL-induced programmed cell death.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) was used to determine mAb specificity.
  • Monoclonal antibodies were employed to study TRAIL and TRAIL receptor expression.
  • Functional assays were conducted to evaluate the modulation of TRAIL-induced apoptosis.

Main Results:

  • The specificity of 10 monoclonal antibodies against TRAIL and its receptors was successfully determined.
  • Expression patterns of TRAIL and its receptors were investigated across different cell types.
  • Certain tested monoclonal antibodies demonstrated the ability to modulate TRAIL-induced programmed cell death.

Conclusions:

  • The characterized monoclonal antibodies provide valuable tools for studying TRAIL signaling pathways.
  • Understanding TRAIL receptor expression is crucial for developing targeted cancer therapies.
  • Modulation of TRAIL-induced apoptosis by specific mAbs offers potential therapeutic strategies.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Related Concept Videos

Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...